Skip to content
DataLookout
Menu

NCT07530796

Safety and Efficacy of scAAV9/AGA Gene Therapy in Participants With Aspartylglucosaminuria (AGU)

StatusEnrolling by Invitation
PhasePhase 1/2
Primary completion (estimated)

At risk: Primary completion moved 2 years 2 months later, primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from May 1, 2029 to Jul 1, 2031 Show 8 more changesShow less
    • Primary endpoint(s) modified
    • Enrolling by invitation only
    • Start date: May 1, 2026 to Nov 1, 2026
    • Eligibility criteria expanded, about 11 words
    • Study completion pushed from May 1, 2032 to Jul 1, 2032
    • Study sites: 0 to 1
    • Interventions: scAAV9/AGA (Genetic) to scAAV9/AGA (Genetic)
    • Secondary endpoints: 2 to 3
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Incidence, severity, and causality of a single dose of scAAV9/AGA in participants with aspartylglucosaminuria (AGU)
Timeframe: Through Day 720

Secondary (2)

Biologic activity following a single dose of scAAV9/AGA in participants with aspartylglucosaminuria (AGU)
Preliminary efficacy following a single dose of scAAV9/AGA in participants with aspartylglucosaminuria (AGU)

Arms and interventions

DANAGALEX (scAAV9/AGA) Gene TherapyExperimental

Cohort 1: adults aged 18-45 years; Cohort 2: adolescents aged 12-17 years; Cohort 3: children aged 4-11 years. All participants receive a single dose of DANAGALEX (scAAV9/AGA). Progression to younger cohorts is subject to protocol-defined safety observation and DSMB review.

Genetic: scAAV9/AGA

Sites

1 site in 1 country

  • Louisiana State University Health Sciences CenterShreveport, Louisiana, United States